676255-04-2

Upstream product

• 769920-49-2 6-(3-piperidin-1-yl-propoxy)-1,2,3,4-tetrahydro-quinoline 
• 98-09-9 benzenesulfonyl chloride 
• 84344-67-2 1-(6-Quinolyloxy)-3-chloropropane 
• 580-16-5 6-hydroxyquinoline 
• 676254-99-2 6-(3-piperidin-1-yl-propoxy)-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 327044-56-4 6-Hydroxy-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 120-15-0 6-methoxy-1,2,3,4-tetrahydroquinoline 
• 3373-00-0 6-hydroxy-1,2,3,4-tetrahydroquinoline 
• 5263-87-6 6-methoxy quinoline 

Downstream Products

• 676255-03-1 1-benzenesulfonyl-6-(3-piperidin-1-yl-propoxy)-1,2,3,4-tetrahydro-quinoline hydrochloride 

Relevant academic research and scientific papers

A robust iron catalyst for the selective hydrogenation of substituted (iso)quinolones

By applying N-doped carbon modified iron-based catalysts, the controlled hydrogenation of N-heteroarenes, especially (iso)quinolones, is achieved. Crucial for activity is the catalyst preparation by pyrolysis of a carbon-impregnated composite, obtained from iron(ii) acetate and N-aryliminopyridines. As demonstrated by TEM, XRD, XPS and Raman spectroscopy, the synthesized material is composed of Fe(0), Fe3C and FeNx in a N-doped carbon matrix. The decent catalytic activity of this robust and easily recyclable Fe-material allowed for the selective hydrogenation of various (iso)quinoline derivatives, even in the presence of reducible functional groups, such as nitriles, halogens, esters and amides. For a proof-of-concept, this nanostructured catalyst was implemented in the multistep synthesis of natural products and pharmaceutical lead compounds as well as modification of photoluminescent materials. As such this methodology constitutes the first heterogeneous iron-catalyzed hydrogenation of substituted (iso)quinolones with synthetic importance.

Synthesis and SAR of novel histamine H3 receptor antagonists

The synthesis and biological evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H3 receptors are reported.

HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula ( I ) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention disclo